Dr. Jacob Thomas, MD
Claim this profileUSC Norris Comprehensive Cancer Center
Expert in Cancer
Studies Squamous Cell Carcinoma
23 reported clinical trials
33 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
TSC1 positive
2Squamous Cell Carcinoma
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Jacob Thomas, MD is currently running
Ipatasertib + Immunotherapy
for Head and Neck Cancer
This trial is testing whether adding a new drug, ipatasertib, to an existing treatment, pembrolizumab, can better treat head and neck cancer that has returned or spread. Ipatasertib may help stop cancer growth, and pembrolizumab helps the immune system attack the cancer. The goal is to see if this combination works better than using pembrolizumab alone. Pembrolizumab has been used in combination with chemotherapy for various cancers, including head and neck cancer, and has shown improved overall survival and response rates.
Recruiting1 award Phase 225 criteria
Darolutamide
for Salivary Gland Cancer
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Leuprolide acetate is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the amount of certain hormones in the body. Giving darolutamide in combination with leuprolide acetate may help to stop the growth of tumor cells that need androgens to grow or shrink them.
Recruiting1 award Phase 2
More about Jacob Thomas, MD
Clinical Trial Related1 year of experience running clinical trials · Led 23 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Jacob Thomas, MD has experience with
- Nivolumab
- PD-1 Inhibitor
- PEOX-based Polymer Encapsulated Paclitaxel FID-007
- Tumor Resection
- Ipatasertib
- Pembrolizumab
Breakdown of trials Jacob Thomas, MD has run
Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jacob Thomas, MD specialize in?
Jacob Thomas, MD focuses on Cancer and Squamous Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jacob Thomas, MD currently recruiting for clinical trials?
Yes, Jacob Thomas, MD is currently recruiting for 11 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Jacob Thomas, MD has studied deeply?
Yes, Jacob Thomas, MD has studied treatments such as Nivolumab, PD-1 inhibitor, PEOX-based Polymer Encapsulated Paclitaxel FID-007.
What is the best way to schedule an appointment with Jacob Thomas, MD?
Apply for one of the trials that Jacob Thomas, MD is conducting.
What is the office address of Jacob Thomas, MD?
The office of Jacob Thomas, MD is located at: USC Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States. This is the address for their practice at the USC Norris Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.